News
12-13-2010, 03:04 AM
Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
More... (http://www.news-medical.net/news/20101213/Boehringer-Ingelheim-reports-positive-results-from-afatinib-phase-IIbIII-LUX-Lung-1-trial-in-advanced-NSCLC.aspx)
More... (http://www.news-medical.net/news/20101213/Boehringer-Ingelheim-reports-positive-results-from-afatinib-phase-IIbIII-LUX-Lung-1-trial-in-advanced-NSCLC.aspx)